Clene Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
CLNN$3.95-0.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $14,645 | $28,821 |
| Marketable securities | — | 6,179 |
| Accounts receivable | — | 143 |
| Inventory | 128 | 37 |
| Prepaid expenses and other current assets | 4,925 | 3,672 |
| Total current assets | 19,698 | 38,852 |
| Restricted cash | 58 | 58 |
| Operating lease right-of-use assets | 3,776 | 4,168 |
| Property and equipment, net | 8,037 | 9,263 |
| TOTAL ASSETS | $31,569 | $52,341 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $1,678 | $1,504 |
| Accrued liabilities | 6,733 | 3,720 |
| Share subscriptions payable | 3,810 | — |
| Operating lease obligations, current portion | 732 | 576 |
| Finance lease obligations, current portion | — | 27 |
| Notes payable, current portion | 10,875 | 14,627 |
| Convertible notes payable, current portion | — | 4,876 |
| Total current liabilities | 23,828 | 25,330 |
| Operating lease obligations, net of current portion | 4,335 | 4,903 |
| Notes payable, net of current portion | 1,668 | 1,894 |
| Convertible notes payable, net of current portion | 5,271 | 5,258 |
| Common stock warrant liabilities | 592 | 1,481 |
| Clene Nanomedicine contingent earn-out liability | — | 75 |
| Initial Stockholders contingent earn-out liability | — | 10 |
| TOTAL LIABILITIES | 35,694 | 38,951 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity (deficit): | ||
| Common stock, $0.0001 par value: 600,000,000 and 300,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 6,857,170 and 6,421,084 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 1 | 1 |
| Additional paid-in capital | 264,225 | 255,913 |
| Accumulated deficit | (268,574) | (242,723) |
| Accumulated other comprehensive income | 223 | 199 |
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (4,125) | 13,390 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $31,569 | $52,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.